Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06778863 · ClinicalTrials.gov registry record · Phase 1
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Clasp Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT06778863: Recruiting Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Clasp Therapeutics.
NCT06778863 is a Phase 1 study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by Clasp Therapeutics. The registered enrollment target is 90 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06778863, a Phase 1 study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by Clasp Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Primary Outcome
Rate of dose-limiting toxicities (DLTs) after infusion of CLSP-1025
Conditions Studied
Interventions
- DRUG CLSP-1025
Study Locations (20)
California
- USC - Norris Comprehensive Cancer Center - Los Angeles
- University of California Davis Comprehensive Cancer Center - Sacramento
- University of California San Francisco - San Francisco
Texas
- Mary Crowley Cancer Research - Dallas
- Baylor University Medical Center - Dallas
- MD Anderson Cancer Center - Houston
Arizona
- HonorHealth Research Institute - Scottsdale
- The University of Arizona Cancer Center - Tucson
New York
- NYU Langone Health - New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Tennessee
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Nashville
- Vanderbilt University Medical Center - Nashville
Florida
- University of Miami - Sylvester Comprehensive Cancer Center - Miami
Illinois
- The University of Chicago Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
What NCT06778863 shows while recruiting
NCT06778863 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which CLSP-1025 is the first listed.
NCT06778863 names 20 study sites across 12 states, led by California, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT06778863 about?
NCT06778863 is a clinical study titled "A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation". Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
What is the current status of trial NCT06778863?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2025-02-28. Estimated completion is 2028-06.
What conditions does trial NCT06778863 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer, Advanced Solid Tumor.
What interventions are being tested in trial NCT06778863?
The interventions under investigation include: CLSP-1025 (DRUG).
Who is sponsoring clinical trial NCT06778863?
This trial is sponsored by Clasp Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06778863 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06778863's enrollment target sits among peer trials
90 613th of 1224 higher than 604 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI